Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Real-time Estimate Cboe BZX  -  10:46 2022-09-27 am EDT
39.53 USD   +5.61%
10:25aZai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commercialize Tivdak
MT
08:41aZai Lab : Corporate Presentation
PU
08:11aZai Lab Ltd : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer

08/03/2022 | 04:11pm EDT

As previously announced, Zai Lab Limited (the “Company”) appointed Joshua Smiley as the Company's Chief Operating Officer, effective on August 1, 2022, following the completion of his leave with his former employer. Mr. Smiley, aged 53, began his career at Eli Lilly and Company in 1995 holding leadership positions across the organization, including serving as Senior Vice President and Chief Financial Officer. Mr. Smiley earned his bachelor's degree in history from Harvard College in 1993.There are no arrangements or understandings between Mr. Smiley and any other person pursuant to which he was appointed as Chief Operating Officer, nor are there any transactions between Mr. Smiley and the Company that would be reportable under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Smiley and any of our directors or executive officers.


© S&P Capital IQ 2022
All news about ZAI LAB LIMITED
10:25aZai Lab Signs Exclusive Collaboration, License Agreement With Seagen to Develop, Commer..
MT
08:41aZai Lab : Corporate Presentation
PU
08:11aZai Lab Ltd : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financ..
AQ
08:03aSeagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for ..
GL
09/21Asian ADRs Move Lower in Wednesday Trading
MT
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
GL
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance..
AQ
09/20Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® Maintenance Treatment i..
CI
09/12DRI Healthcare Trust Acquires Royalty Interest in Zejula, Currently Approved for Treatm..
MT
09/09Asian ADRs Climb Sharply Higher in Friday Trading
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2022 222 M - -
Net income 2022 -468 M - -
Net cash 2022 799 M - -
P/E ratio 2022 -8,33x
Yield 2022 -
Capitalization 3 588 M 3 588 M -
EV / Sales 2022 12,6x
EV / Sales 2023 6,42x
Nbr of Employees 1 951
Free-Float 99,8%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 37,43 $
Average target price 97,22 $
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Joshua L. Smiley Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-40.45%3 588
CSL LIMITED-2.03%89 101
SAMSUNG BIOLOGICS CO.,LTD.-16.06%37 836
BIOGEN INC.-18.41%28 406
WUXI BIOLOGICS (CAYMAN) INC.-48.19%26 052
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-33.88%18 461